{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Telavancin",
    "query": {
      "intervention": "Telavancin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Telavancin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T19:28:08.552Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00077675",
      "title": "Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Gram-positive Bacterial"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "vancomycin or antistaphylococcal penicillin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2004-02",
      "completion_date": "2004-09",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 1,
      "location_summary": "National City, California",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00077675"
    },
    {
      "nct_id": "NCT02013141",
      "title": "Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gram-Positive Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Months to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2014-12",
      "completion_date": "2021-03",
      "has_results": true,
      "last_update_posted_date": "2024-06-24",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013141"
    },
    {
      "nct_id": "NCT06119061",
      "title": "Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Subarachnoid Hemorrhage, Aneurysmal"
      ],
      "interventions": [
        {
          "name": "Telavancin Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aaron Cook",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-07-02",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06119061"
    },
    {
      "nct_id": "NCT02753855",
      "title": "Pharmacokinetics of Telavancin in Normal and Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2016-04",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02753855"
    },
    {
      "nct_id": "NCT00061633",
      "title": "Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Gram-Positive Bacterial",
        "Abscess",
        "Burns",
        "Cellulitis",
        "Ulcer",
        "Wound Infections"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin or antistaphylococcal penicillin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2003-06",
      "completion_date": "2004-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061633"
    },
    {
      "nct_id": "NCT00091819",
      "title": "Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Staphylococcal Skin Infection"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 862,
      "start_date": "2005-01",
      "completion_date": "2006-06",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 1,
      "location_summary": "National City, California",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00091819"
    },
    {
      "nct_id": "NCT01321879",
      "title": "Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection",
        "Bacteremia"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2011-03",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-12-27",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01321879"
    },
    {
      "nct_id": "NCT02288234",
      "title": "Telavancin Observational Use Registry (TOUR)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hospital Acquired Bacterial Pneumonia",
        "Complicated Skin and Skin Structure Infections",
        "Ventilator Associated Bacterial Pneumonia",
        "Gram Positive Infection"
      ],
      "interventions": [
        {
          "name": "Vibativ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1063,
      "start_date": "2014-11",
      "completion_date": "2017-10",
      "has_results": false,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 1,
      "location_summary": "Southfield, Michigan",
      "locations": [
        {
          "city": "Southfield",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02288234"
    },
    {
      "nct_id": "NCT03172793",
      "title": "Telavancin Pharmacokinetics in Cystic Fibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Telavancin Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph L. Kuti, PharmD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2017-08-08",
      "completion_date": "2019-04-17",
      "has_results": false,
      "last_update_posted_date": "2019-10-24",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 5,
      "location_summary": "Hartford, Connecticut • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172793"
    },
    {
      "nct_id": "NCT01238796",
      "title": "A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Diseases",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "telavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2010-12",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-09-04T19:28:08.552Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01238796"
    }
  ]
}